flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017
Yes, Belgium is a hotspot for innovative biopharma and biotechnology industry and we house all the right ingredients for a successful ecosystem: topnotch academic research centers, a large community of SMEs and last but not least: the top-10 biopharma companies all have key activities in Belgium: Novartis, Pfizer, Roche, Sanofi, Merck & C°, Johnson & Johnson, GSK, AstraZeneca, UCB and AbbVie.
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will be speaking at the 7th TERMIS-EU Industry Day taking place from June 26-30, 2017 at the Davos Conference Center, Switzerland.
Celyad publishes additional pre-clinical data in support of THINK trial
Celyad SA (EURONEXT Brussels and Paris: CYAD – NASDAQ Global Market: CYAD), a leader in the discovery and development of CAR-T cell therapies, today announces it has published a special report in the peer-reviewed journal “Future Oncology” summarizing pre-clinical work undertaken on NKR-2, the CAR-T cell therapy currently tested in the company’s THINK trial.
Europa, Vlaanderen, Provincie Oost-Vlaanderen en Stad Gent investeren samen 9,36 miljoen EURO in de Bio Base Europe Pilot Plant
EFRO Vlaanderen en Bio Base Europe Pilot Plant (BBEPP) ondertekenden een overeenkomst voor een investering van 9,36 miljoen EURO in het kader van het IMPACT project. Deze investering wordt gedragen door het Europees Fonds voor Regionale Ontwikkeling (EFRO), Vlaanderen, de Provincie Oost-Vlaanderen, de Stad Gent en de Bio Base Europe Pilot Plant. Hiermee zal nieuwe onderzoeksinfrastructuur worden opgebouwd, specifiek voor gasfermentatie en Down-Stream Processing.